Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are limited due to toxicity and side effects. Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option.
Methotrexate has been an important agent in the management of dermatologic conditions for decades. Although first indicated for the treatment of psoriasis, MTX has been shown to be a successful treatment option for a wide array of skin diseases.
Atopic dermatitis (AD) is a chronic and pruritic inflammatory disease that affects a wide age range of patients causing significant impact on their quality of life. There has been a recently updated consensus paper on the treatment of mild-to-moderate AD published by an expert panel of dermatologists and pediatricians. Family physicians are well equipped to manage...
The term “atopy” was first coined by Cooke and Coca in 1923, derived from the Greek word atopos, which means out of place and denotes an immune reaction that is “strange or eccentric”. Atopic dermatitis (AD) is a chronic, waxing and waning, often symmetric inflammatory eruption that is characterized by pruritus and xerosis.
Allergic contact dermatitis (ACD) is more frequent in the pediatric population and in children with atopic dermatitis (AD) than has hitherto been appreciated. Patch testing, which is mediated by different immune mechanisms than prick skin testing, is both safe and diagnostically useful for individuals with AD.
Learn about cannabinoids influence on skin growth control, homeostasis, melanoma, acne, pruritus, inflammation, atopic dermatitis, and other skin conditions.
The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.
Practical guidelines for the management of Chronic Hand Dermatitis were published in the Skin Therapy Letter, Family Practice Edition (October 2016). This series of cases using Alitretinoin (Toctino®), is a follow on to that publication to put the guidelines into context.
This real-world case series intends to illustrate a variety of moderate-to-severe AD patient cases to help guide discussions around abrocitinib and describe its treatment strategies used by experts in the field.
Atopic dermatitis (AD), or eczema, is a common, chronic, relapsing, genetically determined inflammatory skin disorder. This article discusses the role of Staphylococcus aureus (S. aureus) as a factor to consider.
This article discusses atopic dermatitis, its pathogenesis, and general treatment principles as well as specific therapeutic options.
Atopic eczema is a chronic condition and a long view is necessary for disease control and management. This article discusses the important role of the skin barrier and how it may be a target for therapeutics in treating atopic eczema.
Tralokinumab is an effective and safe treatment for adult patients with moderate-to-severe AD. It may be used alone or in combination with TCS. This biologic can be considered first-line treatment after failure of or intolerance to topical therapies.
Racial/Ethnic Variations in the Skin Barrier of Canadians: Implications for Skincare Recommendations Promoting a Healthy Skin Barrier and Mitigation...
Skin barrier differences and variations in the presentation of common dermatoses such as xerosis and atopic dermatitis (AD) have been reported in racial/ethnic Canadian patients. This review discusses skin barrier differences and explores the role of ceramide-containing skin care in promoting a healthy skin barrier and mitigating AD.
This article reviews atopic dermatitis, and its shift in the philosophy behind treatment and management. Preventative therapy, long-term strategy, and focus on quality of life.
This paper examines the pathogenesis of atopic dermatitis, the skin barrier, and the role that ceramides can play in therapy.
Prednicarbate is a nonhalogenated corticosteroid that is used in the treatment of inflammatory skin diseases, for example atopic dermatitis. It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.
Atopic dermatitis is a highly pruritic inflammatory disorder of the skin characterized by onset in infancy or childhood and a chronically relapsing course. Mainstay treatments are emollients and topical corticosteroids, but the latter are limited by side-effects from longterm use.
This article reviews topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) to manage inflammatory conditions, its risks with long-term use, and the role of moisturizing as important therapeutic adjuncts.
A group of dermatologists with extensive experience in managing pediatric and adult patients with atopic dermatitis developed practical recommendations for the management of atopic dermatitis based on expert consensus opinion and the best available medical evidence.
An overview to AD care and focus our review to topical agents used in AD including topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) and discuss the newest topical agent accessible in the physician's armamentarium, crisaborole.
Retapamulin: What is the Role of this Topical Antimicrobial in the Treatment of Bacterial Infections in Atopic Dermatitis?
In atopic dermatitis, the stratum corneum of patients appears to have alterations that predispose them to colonization and invasion by various bacteria. Retapamulin appears to be a much needed antimicrobial option for treating the atopic dermatitis population due to their common carriage of bacterial pathogens.
Fusidic acid/betamethasone 17-valerate cream (Fucibet®) is a cosmetically acceptable, well tolerated cream which is hydrating and improves the TSS dermatitis score in secondarily infected dermatitis. In addition, it clears bacteria in infected dermatitis better than vehicle suggesting that improving the dermatitis with a steroid might be synergistic, perhaps through a reduction in bacterial load.
Mild to moderate atopic dermatitis (AD) is often controlled by behavioral measures such as skincare and avoidance of triggers in addition to topical treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).
A Look at Epidermal Barrier Function in Atopic Dermatitis: Physiologic Lipid Replacement and the Role of Ceramides
This review summarizes and discusses the role and efficacy of moisturizers, particularly the more recently introduced ceramide-based formulations, in the skin care regimen of patients with both active and quiescent atopic dermatitis.
The exact mechanism of action of leukotriene receptor antagonists in Atopic Dermatitis is not known. In small clinical and case studies, montelukast was found to be a safe and effective alternative or steroid-sparing therapy in the management of patients with atopic dermatitis.
Crisaborole represents a novel and efficacious therapeutic approach for the treatment of mild to moderate Atopic Dermatitis and demonstrates early and continued decrease in pruritus, which improves quality of life and reduces the potential risk of infection and scarring.
Tacrolimus ointment (Protopic®, Fujisawa) is an effective agent in a class of topical immunomodulators. It has been shown to be safe and effective in adults and children with Atopic Dermatitis in short- and long-term treatments.
Parabens have been under scrutiny for some time with the very limited reports of paraben-induced allergic contact dermatitis. This article discusses the controversy, the data, and how the facts may not match up with the concern.
Topical ruxolitinib shows promise in various dermatological conditions, including atopic dermatitis, vitiligo, psoriasis, and lichen planus, with a favorable safety profile compared to oral JAK inhibitors. However, its effectiveness in alopecia areata remains inconclusive.
Pimecrolimus is an immunomodulating medication that inhibits production of inflammatory cytokines in the skin and this compound was specifically developed for the treatment of inflammatory skin diseases.
Atopic dermatitis is a chronic inflammatory skin condition. It has a relapsing course characterized by flare-ups of acute eczema on a background of chronically dry skin. The association of atopic dermatitis (AD) with asthma and allergic rhinitis is referred to as the atopic triad.
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, represent a new class of medication that have broad potential to treat dermatologic disease.
Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.
Atopic dermatitis (AD) or eczema is a chronic, relapsing skin condition that can lead to xerosis, pruritus, and patches of dermatitis. Coping with the physical and emotional aspects of AD can significantly impact the quality of life. It is most common in childhood, as many patients seem to outgrow the condition by adulthood.
Moisturizers and Cleansers in the Management of Skin Conditions Caused by Personal Protective Equipment and Frequent Handwashing
Routine moisturization with non-irritating, pH-adjusted, ceramide-based products and gentle cleansing with a pH-adjusted cleanser can treat the unique dermatological challenges posed by COVID-19.
This article discusses the role of S. aureus, on atopic dermatitis. Taking a proactive approach to treatment, and control S. aureus may have benefits for the management of inflammation.
TCIs have an important place in the therapeutic armamentarium for AD. They are approved as second line agents for individuals >2 years of age, and have a good safety profile when used short-term or intermittently long-term.
Herbal remedies are largely unregulated, but often talked about among patients. Many may have scientific merit and clinical benefit, but they are still scientifically invalid and inadequately monitored. Dermatologists need information about herbal remedies to better serve their Atopic Dermatitis patients.
12Page 1 of 2